IGM Biosciences Overview
- Year Founded
-
1993
- Status
-
Public
- Employees
-
198
- Stock Symbol
-
IGMS
- Share Price
-
$9.90
- (As of Wednesday Closing)
IGM Biosciences General Information
Description
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.
Contact Information
Website
www.igmbio.comCorporate Office
- 325 East Middlefield Road
- Mountain View, CA 94043
- United States
Corporate Office
- 325 East Middlefield Road
- Mountain View, CA 94043
- United States
IGM Biosciences Stock Performance
As of 04-Dec-2024, IGM Biosciences’s stock price is $9.90. Its current market cap is $589M with 59.3M shares.
(As of Wednesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $9.90 | $10.55 | $5.58 - $22.50 | $589M | 59.3M | 312K | -$3.61 |
IGM Biosciences Financials Summary
As of 30-Sep-2024, IGM Biosciences has a trailing 12-month revenue of $2.92M.
|
In Thousands, USD |
TTM 30-Sep-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
|---|---|---|---|---|
| EV | 764,123 | 139,454 | 287,420 | 721,970 |
| Revenue | 2,918 | 2,130 | 1,069 | 0 |
| EBITDA | (225,779) | (255,204) | (222,062) | (160,839) |
| Net Income | (219,843) | (246,416) | (221,102) | (165,164) |
| Total Assets | 304,508 | 423,411 | 513,499 | 298,127 |
| Total Debt | 45,857 | 40,506 | 41,172 | 28,759 |
IGM Biosciences Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
IGM Biosciences Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
IGM Biosciences Comparisons
Industry
Financing
Details
IGM Biosciences Competitors (70)
One of IGM Biosciences’s 70 competitors is Compass Therapeutics, a Formerly VC-backed company based in Boston, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Compass Therapeutics | Formerly VC-backed | Boston, MA | ||||
| Mustang Bio | Corporation | Worcester, MA | ||||
| Kite Pharma | Formerly VC-backed | Santa Monica, CA | ||||
| Adaptimmune Therapeutics | Formerly VC-backed | Abingdon, United Kingdom | ||||
| Instil Bio | Formerly VC-backed | Dallas, TX |
IGM Biosciences Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
IGM Biosciences Patents
IGM Biosciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-3240270-A1 | Anti-cd38 binding molecules and uses thereof | Pending | 03-Feb-2022 | ||
| AU-2023216348-A1 | Anti-cd38 binding molecules and uses thereof | Pending | 03-Feb-2022 | ||
| FR-3124067-B1 | Implantable device comprising external mobilization means for the formation of articular cartilage | Active | 17-Jun-2021 | ||
| FR-3124067-A1 | Implantable device comprising external mobilization means for the formation of articular cartilage | Active | 17-Jun-2021 | ||
| JP-2024521517-A | Implantable device comprising external mobilization means for formation of articular cartilage - patent application | Pending | 17-Jun-2021 | A61L27/3654 |
IGM Biosciences Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
IGM Biosciences Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
IGM Biosciences ESG
Risk Overview
Risk Rating
Updated December, 15, 2022
38.97 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,100
Rank
Percentile
Pharmaceuticals
Industry
of 851
Rank
Percentile
Pharmaceuticals
Subindustry
of 424
Rank
Percentile
IGM Biosciences FAQs
-
When was IGM Biosciences founded?
IGM Biosciences was founded in 1993.
-
Where is IGM Biosciences headquartered?
IGM Biosciences is headquartered in Mountain View, CA.
-
What is the size of IGM Biosciences?
IGM Biosciences has 198 total employees.
-
What industry is IGM Biosciences in?
IGM Biosciences’s primary industry is Biotechnology.
-
Is IGM Biosciences a private or public company?
IGM Biosciences is a Public company.
-
What is IGM Biosciences’s stock symbol?
The ticker symbol for IGM Biosciences is IGMS.
-
What is the current stock price of IGM Biosciences?
As of 04-Dec-2024 the stock price of IGM Biosciences is $9.90.
-
What is the current market cap of IGM Biosciences?
The current market capitalization of IGM Biosciences is $589M.
-
What is IGM Biosciences’s current revenue?
The trailing twelve month revenue for IGM Biosciences is $2.92M.
-
Who are IGM Biosciences’s competitors?
Compass Therapeutics, Mustang Bio, Kite Pharma, Adaptimmune Therapeutics, and Instil Bio are some of the 70 competitors of IGM Biosciences.
-
What is IGM Biosciences’s annual earnings per share (EPS)?
IGM Biosciences’s EPS for 12 months was -$3.61.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
